AM-14 Antibody Formulation Viscosity and Pain Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biopharmaceutical formulations of AM-14 face challenges in achieving high concentrations with low viscosity, stability, and comfort during administration, as well as inducing stinging/pain upon subcutaneous injection.
Innovation Solution
Development of AM-14 formulations with high concentrations (60-250 mg/ml) using glutamate-based buffers at 10 mM glutamate, combined with excipients like sucrose, glycine, and polysorbate 20, which maintain low viscosity, stability, and reduce discomfort during administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If biopharmaceutical formulations use high concentrations of AM-14, then the dosage efficiency and treatment effectiveness are improved, but the viscosity increases making administration difficult
Solution Approach 1:
The patent applies parameter changes by systematically optimizing formulation parameters including buffer type (acetate, citrate, phosphate, histidine, or glutamate), pH (4.0-6.0), excipient concentrations (sucrose 1-10%, polysorbate 20 0.01-0.1%, glycine 0.1-5%), and protein concentration (60-250 mg/ml) to achieve the desired balance between high concentration and low viscosity
Solution Approach 2:
The patent employs composite materials by combining AM-14 antibody with multiple excipients including sugars (sucrose, trehalose, mannitol), amino acids (glycine, glutamate), surfactants (polysorbate 20, polysorbate 80), and buffers to create a synergistic formulation system that maintains stability while reducing viscosity at high concentrations
2Quantity of substance
If biopharmaceutical formulations use high concentrations of AM-14, then the treatment effectiveness is improved, but the stability of the formulation deteriorates
Solution Approach 1:
The patent applies beforehand cushioning by incorporating stabilizing excipients (sucrose, trehalose, mannitol, glycine, glutamate) and surfactants (polysorbate 20, polysorbate 80) into the formulation before administration to prevent aggregation, degradation, and other stability issues that may arise at high concentrations
Solution Approach 2:
The patent optimizes pH (4.0-6.0) and ionic strength through buffer selection and concentration adjustments to maintain the electrostatic repulsion and conformational stability of AM-14 at high concentrations, preventing aggregation and degradation
3Ease of operation
If biopharmaceutical formulations are designed for subcutaneous injection, then the ease of administration is improved, but stinging and pain occur at the injection site
Solution Approach 1:
The patent converts potentially harmful high concentration and low pH characteristics into benefits by carefully selecting buffers (acetate, citrate, phosphate, histidine, or glutamate) and excipients that, while enabling high concentration formulation, also have soothing properties that reduce injection-site stinging and pain when administered subcutaneously
Data Source
AI summary
The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.